Eventide Asset Management - TURNING POINT THERAPEUTICS I ownership

TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of TURNING POINT THERAPEUTICS I
ValueSharesWeighting
Q3 2021$38,397,000
-14.9%
578,0000.0%0.51%
-16.5%
Q2 2021$45,096,000
-5.6%
578,000
+14.5%
0.61%
-14.4%
Q1 2021$47,768,000
-32.8%
505,000
-13.4%
0.71%
-35.0%
Q4 2020$71,039,000
+112.3%
583,000
+52.2%
1.09%
+66.3%
Q3 2020$33,459,000
+35.3%
383,0000.0%0.66%
+21.7%
Q2 2020$24,738,000383,0000.54%
Other shareholders
TURNING POINT THERAPEUTICS I shareholders Q4 2020
NameSharesValueWeighting ↓
venBio Partners LLC 708,233$44,116,00018.91%
Corriente Advisors, LLC 285,000$17,753,0009.54%
Cormorant Asset Management, LP 3,396,650$211,577,0008.44%
Opaleye Management Inc. 340,500$21,210,0004.16%
Orbimed Advisors 2,745,327$171,006,0002.44%
Parkman Healthcare Partners LLC 101,434$6,318,0001.82%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 35,000$2,179,0000.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 366,000$22,798,0000.73%
Artal Group S.A. 300,000$18,687,0000.72%
DAFNA Capital Management LLC 30,408$1,894,0000.65%
View complete list of TURNING POINT THERAPEUTICS I shareholders